resTORbio (TORC) Stock Price, News & Analysis

Company Overview

Adicet Bio, Inc. is a biotechnology company which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Key Stats

• Today's Range: $0.71 to $0.74
• 50-Day Range: $2.28 to $14.77
• 52-Week Range: $0.86 to $10.50
• Volume: 232,536 shs
• Average Volume: 1.15 million shs
• Market Capitalization: $26.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TORC Stock Analysis - Frequently Asked Questions

How were resTORbio's earnings last quarter?

resTORbio, Inc. (NASDAQ:TORC) released its quarterly earnings results on Thursday, July, 30th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.07.

When did resTORbio IPO?

resTORbio (TORC) raised $86 million in an initial public offering on Friday, January 26th 2018. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Leerink Partners and Evercore ISI acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What other stocks do shareholders of resTORbio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that resTORbio investors own include Novavax (NVAX), VBI Vaccines (VBIV), AbbVie (ABBV), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE) and CRISPR Therapeutics (CRSP).

Company Calendar

• Last Earnings: 7/30/2020
• Today: 8/27/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:TORC
• CIK: 1720580
• Web: www.restorbio.com
• Phone: (857) 315-5521
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$82.74 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -78.12%
• Return on Assets: -71.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 20.69
• Quick Ratio: 20.69

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.24 per share
• Price / Book: 0.33

Miscellaneous

• Outstanding Shares: 36,454,000
• Free Float: N/A
• Market Cap: $26.86 million
• Optionable: Not Optionable
• Beta: 2.43